Author at Microdose

Patrick McConnell

Patrick McConnell is a freelance writer who first became fascinated with psychedelics during an anti-drug presentation in high school. Previously he has worked as a treeplanter, orchardist, and cannabis farmer. After drinking ayahuasca in 2020, he quit his job, sold everything he owned, and now resides in the Peruvian Andes with his wife and cat.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Industry

13 Oct 2022

A Look at Web3 and Psychedelic IP

As companies move themselves toward potential commercialization of psychedelic medicines, a great deal of speculation and attention is being placed on intellectual property (IP) and the future of Web3....

By Patrick McConnell

Industry, Science

4 Oct 2022

Is Ketamine Telehealth Here to Stay?

Ketamine telehealth has been booming....

By Patrick McConnell

Culture, Science

23 Sep 2022

How Interdisciplinary Research Could Reveal Psychedelics’ Blind Spots

Dr....

By Patrick McConnell

Industry

13 Sep 2022

Decentralizing the Future: Crypto and Psychedelics

Psychedelics have long been a decentralized network....

By Patrick McConnell

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

16 Aug 2022

Therapsil Sues Canadian Government Over Psilocybin Access

Non-profit Therapsil, as well as seven other patients and one medical professional, are suing the Canadian government....

By Patrick McConnell

Law & Politics

5 Aug 2022

Psychedelic Reform and Decrim Update

By Patrick McConnell

Culture

4 Aug 2022

Review: Michael Pollan’s How to Change Your Mind

In the first episode of Netflix's How to Change Your Mind, Michael Pollan showed Netflix viewers the history of LSD, which we summarized here....

By Patrick McConnell

Culture

27 Jul 2022

Music & Psychedelics: Past, Present, and Future

Music and psychedelics have a long history and are powerful therapies in themselves — but when combined, their effects can stack for impressive outcomes....

By Patrick McConnell

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

Patrick McConnell is a freelance writer who first became fascinated with psychedelics during an anti-drug presentation in high school. Previously he has worked as a treeplanter, orchardist, and cannabis farmer. After drinking ayahuasca in 2020, he quit his job, sold everything he owned, and now resides in the Peruvian Andes with his wife and cat.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads